Tirzepatide data: safety always comes first!

Expert opinion on drug safety

The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions.

Journal of the American Association of Nurse Practitioners

Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists.

Vision (Basel, Switzerland)

Functional Performance of Silk Nanoparticles for Oral Drug Delivery.

ACS applied materials & interfaces

Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection.

Pharmaceuticals (Basel, Switzerland)

Oral GLP-1-Based Therapeutics in the Obesity-Metabolic Syndrome-Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies.

Pharmaceuticals (Basel, Switzerland)

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.

Pharmaceutics

Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.

Pharmaceutics

Everyone says peptides cause cancer. I pulled the studies. Here's what they actually show. 06:25 BPC-157 08:40 DSIP 09:54 Epitalon 12:15 GHK-Cu 14:45 KPV 16:03 LL-37 18:41 MOTS-c 20:00 Retatrutide 21:19 Semaglutide 22:24 SS-31 24:13 Thymosin Alpha-1 25:47 Tirzepatide https://t.co/2RBkMubEQP

Popular obesity medications significantly lower overall cancer risk, study finds. The breakthrough class of obesity medications, including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP receptor agonists like tirzepatide, continue to make waves in modern medicine. https://t.co/Bul3Icqy4F

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

What 2026 research-chem buyers actually order — top 10 by share of all in-scope COAs in our corpus over the last 60 days: Retatrutide — 10.4% Tirzepatide — 8.5% BPC-157 — 7.8% GHK-Cu — 4.8% Tesamorelin — 4.4% MOTS-C — 4.1% Ipamorelin — 3.8% NAD+ — 3.2% Semaglutide — 3.1% TB-500

Why Retatrutide is Better Than Other GLP-1s: 1. Triple Action Power • Retatrutide activates GLP-1, GIP, and glucagon receptors — most others only target GLP-1 (like Semaglutide) or GLP-1 + GIP (like Tirzepatide). https://t.co/d5qjmF2BX1 https://t.co/wOBoPEcVsW